{"doi":"10.1002/dat.20531","title":"Belatacept in renal transplantation","abstract":"<jats:title>Abstract</jats:title><jats:p>Belatacept is a novel agent that prevents CD28 signaling and inhibits T‐cell activation by costimulation blockade. It was developed from abatacept (CTLA‐4 Ig), the first recombinant immunoglobulin fusion protein that contains extracellular portion of CTLA‐4, and the Fc domain of IgG. Early studies have shown that belatacept recipients show comparable patient and graft survival, superior renal function and renal biopsy data compared with cyclo‐sporine‐treated patients. Newer biologic agents such as belatacept offer the promise of real change—due to their lack of mechanism‐related toxic effects—and help monitor drug administration, thereby improving compliance. Belatacept is a potential option for maintenance biologic therapy without a calcineurin inhibitor, accompanied by excellent mid‐term results with yet unknown long‐term safety and efficacy. The increased rate of TCMR and possibly central nervous system post‐transplantation lymphoproliferative disorder are worrisome and need to be further elucidated.</jats:p>","journal":"Dialysis &amp; Transplantation","year":2011,"id":661516,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1726945,"name":"K. Vinay Ranga","orcid":null,"position":1,"is_corresponding":false},{"id":270998,"name":"Bruce Kaplan","orcid":"0000-0003-3400-642X","position":2,"is_corresponding":false},{"id":1726943,"name":"Sarah E. Yost","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Belatacept in renal transplantation","abstract":"<jats:title>Abstract</jats:title><jats:p>Belatacept is a novel agent that prevents CD28 signaling and inhibits T‐cell activation by costimulation blockade. It was developed from abatacept (CTLA‐4 Ig), the first recombinant immunoglobulin fusion protein that contains extracellular portion of CTLA‐4, and the Fc domain of IgG. Early studies have shown that belatacept recipients show comparable patient and graft survival, superior renal function and renal biopsy data compared with cyclo‐sporine‐treated patients. Newer biologic agents such as belatacept offer the promise of real change—due to their lack of mechanism‐related toxic effects—and help monitor drug administration, thereby improving compliance. Belatacept is a potential option for maintenance biologic therapy without a calcineurin inhibitor, accompanied by excellent mid‐term results with yet unknown long‐term safety and efficacy. The increased rate of TCMR and possibly central nervous system post‐transplantation lymphoproliferative disorder are worrisome and need to be further elucidated.</jats:p>","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"19162232","pmcid":null,"openalex_id":"https://openalex.org/W1971245044","authors":[],"funders":[],"total_grants":0,"fwci":0.1662,"citation_percentile":0.45563549,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2016,"count":1},{"year":2019,"count":1},{"year":2021,"count":1}],"oa_status":"bronze","license":"http://onlinelibrary.wiley.com/termsAndConditions#vor","oa_locations":[{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dat.20531","host_type":"journal"},{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/dat.20531","host_type":"publisher"},{"url":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fdat.20531","host_type":"publisher"},{"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/dat.20531","host_type":"publisher"},{"url":"https://doi.org/10.1002/dat.20531","host_type":"journal"}],"fields_of_study":["Renal Transplantation Outcomes and Treatments","Complement system in diseases","Pneumocystis jirovecii pneumonia detection and treatment"],"mesh_terms":[],"keywords":["Belatacept","Abatacept","Medicine","Calcineurin","Transplantation","Co-stimulation","Immunology","Pharmacology","Kidney transplantation","T cell","CD28","Internal medicine","Antibody","Immune system","Kidney transplant","Rituximab"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-12T11:09:40.623061Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}